Asthma
Oral Dexpramipexole.
Our Novel Candidate for
Eosinophilic Asthma
An Uncommon Approach to a Common
Respiratory Disorder
Dexpramipexole
Eosinophils & Asthma How Do They Relate?

50%
of all patients suffering with severe asthma have elevated numbers of eosinophils in their blood and lungs.

High levels of eosinophils increase the risk of asthma attacks and lung damage.

At present, the only treatments for eosinophilic asthma come in the form of injections or infusions.

Dexpramipexole is an experimental drug shown to block eosinophils from maturing in the bone marrow, and is under investigation as a potential treatment for eosinophilic asthma.

Ongoing clinical research on the role of eosinophils in asthma has already created benefits for many patients.
Our Goal is to demonstrate the safety and effectiveness of dexpramipexole
Phase 2 trial data will be reported soon. We welcome you to follow our progress.
Latest Publications about Dexpramipexole
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Discover this News
09.16.2020Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
Discover this News
12.02.2019Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
Discover this News
07.09.2019Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Discover this News
04.24.2019Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
Discover this News
03.20.2019Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma
Discover this News
01.16.2019Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
Discover this News
09.08.2018Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases
Discover this News
05.22.2018NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases
Discover this News
05.10.2018Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood
Discover this News